Skip to main content
Give
Edit Icon - Click to update your profileUpdate Your Profile

Ann M. Farese, MA, MS

Academic Title:

Adjunct Assistant Professor

Primary Appointment:

Radiation Oncology

Email:

afarese@som.umaryland.edu

Phone (Primary):

(410) 706-5254

Phone (Secondary):

(410) 706-5270

Download CV

Education and Training

M.S. - Biology, The American University, Washington, D.C.,05/1993
M.A. - Management and Supervision: Health Care Administration, Central Michigan University, Mt. Pleasant, MI., 12/1982
B.S. - Medical Technology, Marquette University, Milwaukee, WI., 05/1974

Biosketch

I have 30 years of experience as a researcher in the field of radiation biology and over 10 years as a clinical laboratory science with extensive experience in the field of hematology. During my career I have investigated the innate and adaptive immune responses of multiple animal models during the acute radiation syndrome with emphasis on hematopoietic and gastrointestinal syndromes. I also have also managed the large animal hematology laboratory, extramural contracts and performed research focused on the use of hematopoietic growth factors to mitigate radiation injury.

Currently, at University of Maryland, Baltimore I serve as Co-PI in the development and use of nonhuman primate models of the acute and delayed radiation syndromes in the hematopoietic, gastrointestinal and lung systems. I was charged with the implementation of Good Laboratory Practices at UMB and have been Study Director on three GLP-compliant studies.  I served as the Study Director of a GLP-compliant study that resulted in an FDA study audit, a joint FDA Advisory Committee Meeting and approval by the FDA of the first-ever drug, Neupogen® approved for use in the event of a nuclear disaster. I served as Co-investigator in a second GLP-compliant study that contributed to the FDA approval of Neulasta® as a medical countermeasure for high dose radiation exposure.

I have been an invited speaker to national and international audiences on animal model development and the efficacy of hematopoietic growth factors to treat myelosuppresion and myeloablation. I have served as an administered hoc reviewer for Experimental Hematology, Haematologica, Bone Marrow Transplantation, International Journal of Radiation Biology, Journal of Controlled Release, European Journal of Haematology, Molecular Therapy, Biosimilars, BioMed Research International and Comparative Medicine. In summary, I have demonstrated a consistent and substantial record of accomplishment as an investigator, laboratory manager, scientific author and speaker in the field of radiation research.

Research/Clinical Keywords

Hematopoietic growth factors and in vivo effects of high dose irradiation exposure and the treatment of the acute radiation syndrome for major organ systems, i.e., hematopoietic, gastrointestinal, lung, heart and kidney.

Highlighted Publications

Farese, A.M., Cohen, M.V., Katz, B. P, Smith, C. P.  Jackson III, W., Cohen, D.M., MacVittie, T.J. (2012) A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management.  J Health Phys, 103(4):367-382.

Farese, A.M., Cohen, M.V., Katz, B. P, Smith, C. P. Gibbs, A.M., Cohen, D.M.,  MacVittie, T.J. (2013)  Filgrastim improves survival in lethally irradiated nonhuman primates. Rad Research, 179(1):89-100.

Farese, A.M., Brown, C.R., Smith, C. P. Gibbs, A.M., Katz, B. P, Johnson, C.S., Prado, K.,  MacVittie, T.J. (2014) The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent. J Health Phys 106(1):39-47.

Hankey, K.G, Farese A.M., Blaauw, E.C., Gibbs, A.M., Smith, C.P., Katz, B.P., Tong, T., Prado, K.L.,MacVittie, T.J. (2015 egfilgrastim Improves Survival of Lethally Irradiated Nonhuman Primates. Rad Research 83(6): 643-655.

Additional Publication Citations

Farese, A.M., Cohen, M.V., Stead, R.B., Jackson III, W., MacVittie, T.J. (2012) Peg-filgrastim, administered in an abbreviated schedule, significantly improves neutrophil recovery after high-dose, radiation-induced myelosuppression in rhesus macaques. Rad Research, 178(5):403-13.

MacVittie, T.J., Farese, A.M., Bennett, A., Gelfond, D., Shea-Donohue, T., Tudor, G., Booth, C., McFarland, E., Jackson III, W. (2012) The Acute Gastrointestinal Sub-Syndrome of the Acute Radiation Syndrome: A rhesus macaque model. J Health Phys, 103(4):411-426.

MacVittie, T.J., Bennett, A., Booth, C., Garofalo, M., Tudor, G., Ward, A., Shea-Donohue, T., Gelfond, D., McFarland, E., Jackson III, W., Lu, W., Farese, A.M., (2012) The prolonged gastrointestinal syndrome in rhesus macaques: the relationship between gastrointestinal, hematopoietic, and delayed multi-organ sequelae following acute, potentially lethal, partial-body irradiation. J Health Phys, 103(4):417-453.

MacVittie, T.J., Bennett, A., Cohen, M.V., Farese, A.M., Higgins, A., Hankey, K.G., (2014) Immune Cell Reconstitution After Exposure to Potentially Lethal Doses of Radiation in the Nonhuman Primate. J Health Phys 106(1):84-96.

Garofalo, M.C., Bennett, A., Farese, A.M., Ward, A.A., Taylor-Howell, C., Cui, W., Gibbs, A., Lasio, G., Jackson, W., MacVittie, T.J. (2014) The delayed pulmonary syndrome following acute high-dose irradiation: A rhesus macaque model. J Health Phys 106(1):56-72.

Garofalo, M.C., Ward, A.A., Farese, A.M., Bennett, A., Taylor-Howell, C., Cui, W., Gibbs, A., Prado, K., Jackson, W., MacVittie, T.J. (2014) A Pilot Study in Rhesus Macaques to Assess the Treatment Efficacy of a Small Molecular Weight Catalytic Metalloporphyrin Antioxidant (AEOL 10150) in Mitigating Radiation-Induced Lung Damage.  J Health Phys 106(1):73-83

MacVittie, T.J., Farese, A.M., Jackson, III, W. (2015) The hematopoietic syndrome of the acute radiation syndrome in rhesus macaques: A systematic review of the lethal dose response relationship. Health Phys. 109(5): 342-36

Farese, A.M., Hankey, K.G., Cohen, M.V. MacVittie, T.J., (2015) Lymphoid and myeloid recovery in rhesus macaques following total body x-irradiation. Health Phys. 109(5):414-426

MacVittie, T.J., Bennett, A.W., Farese, A.M., (2015) The effect of radiation dose and variation in Neupogen® initiation schedule on the mitigation of myelosuppression during the concomitant GI-ARS and H-ARS in a nonhuman primate model of high-dose exposure with marrow sparing. Health Phys. 109(5):427-439

Thrall, K., Love, R., O’Donnell, K., Manning, R., Farese, A.M., MacVittie, T.J. (2015) An interlaboratory validation of the radiation dose response relationship (DRR) for the H-ARS in the rhesus macaque. Health Phys. 109(5): 502-510

Farese, A.M., MacVittie, T.J., (2015) Filgrastim for the treatment of the hematopoietic acute radiation syndrome. Drugs of Today 51(9): 537-548

Shea-Donohue, T., Fasano, A., Zhao, A., Notari, L., Yan, S., Sun, R., Bohl, J.A., Desai, N., Tudor, G., Morimoto, M., Booth, C., Bennett, A., Farese, A.M., MacVittie, T.J. (2016) Mechanisms contributing to the sequelae of the prolonged GI syndrome in mice. Radiat. Res. 185, 591-60

MacVittie, T.J., Gibbs, A., Farese, A.M., Barrow, K., Taylor-Howell, C., Bennett, A., Prado, K., Jackson III, W. (2017) AEOL10150 mitigates radiation-induced lung injury in the nonhuman primate: morbidity and mortality is administration schedule dependent. Radiat. Res. 87(3):298-318; DOI: 10.1667/RR4413.1

Prado, C., MacVittie, T.J., Bennett, A.W., Kazi, A., Farese, A.M., Prado, K. (2017) Organ doses associated with partial-body irradiation with 2.5% bone-marrow sparing of the nonhuman primate: A retrospective study. Radiat. Res. 188(6):615-625. DOI: 10.1667/RR14804.1.

Carter, C., Jones, J., Farese, A., MacVittie, T. Kane, M.  (2017) Lipidomic dysregulation within the lung parenchyma following whole-thorax lung irradiation: Markers of injury, inflammation and fibrosis detected by MALDI-MSI. Scientific Reports. 7(10343):1-13. DOI: 10.1038/s41598-017-10396-w

Cohen, E.P, Hankey, K., Bennett, A., Farese, A., Parker, G.A., MacVittie, T. (2017) Acute and chronic kidney injury in a non-human primate model of partial-body irradiation with bone marrow sparing. Radiat. Res. 188(6):661-671. DOI: 10.1667/RR24857.1

Complete Bibliography:

http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/42558001/?sort=date&direction=ascending

Research Interests

C1. Elucidating the effects of radiation exposure either alone or in combination with another agent such as thermal injury or sepsis on survival and particularly the hematopoietic response in animal models. With the discovery, purification and manufacturing of hematopoietic growth factors, these models became invaluable in the early studies demonstrating the efficacy of recombinant hematopoietic growth factors to rescue severely myelosuppressed animals. These studies performed in our laboratory contributed to the database for Investigational New Drug applications to the FDA by several biotechnology companies such as Amgen, Inc., Immunex, Corp., Sandoz and Monsanto.

  • Williams, D.E., Farese, A.M., Dunn, J., Park, L.S., Frieden, E., Seiler, F.R., MacVittie, T.J. (1993) A GM-CSF/IL-3 fusion protein promotes neutrophil and platelet recovery in sublethally irradiated rhesus monkeys. Biotechnology Therapeutics, 4:17.
  • MacVittie, T.J., Farese, A.M., Patchen, M.L., Myers, L.A. (1994) Therapeutic efficacy of recombinant interleukin-6 alone and combined with recombinant human interleukin-3 in a nonhuman primate model of high dose, sublethal radiation-induced marrow aplasia. Blood 84: 2515-2522.
  • Farese, A.M., Hunt, P., Grab, L. B., MacVittie, T. J. (1996) Enhancement of hematopoietic reconstitution in nonhuman primates following radiation-induced marrow aplasia by the combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony stimulating factor. J Clin Inves 97:2145-2151.
  • MacVittie, T.J., Farese, A. M., Lind, L. B., Baum, C. M., Burton, E., McKearn, J. P. (2000) Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood 95:837-845.

C2. Development of well characterized animal models to test the efficacy of potential medical countermeasures to treat humans in the event of high dose radiation exposure. Following the events of September 11, 2001, and the creation of the FDA “Animal Rule” our laboratory developed well-codified nonhuman primate modelsof the acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE).

  • Farese AM, Cohen MV, Katz BP, Smith C P, Jackson III W, Cohen D, MacVittie TJ. (2012) A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management. J Health Phys, 103(4):367-382.
  • MacVittie TJ, Farese AM, Bennett A, Gelfond D, Shea-Donohue T, Tudor G, Booth C, McFarland E, Jackson III W (2012) The Acute Gastrointestinal Sub-Syndrome of the Acute Radiation Syndrome: A rhesus macaque model. J Health Phys, 103(4):411-426.
  • MacVittie TJ, Bennett A, Booth C, Garofalo M, Tudor G, Ward A, Shea-Donohue T, Gelfond D, McFarland E, Jackson III W, Lu W, Farese AM, (2012) The prolonged gastrointestinal syndrome in rhesus macaques: the relationship between gastrointestinal, hematopoietic, and delayed multi-organ sequelae following acute, potentially lethal, partial-body irradiation. J Health Phys, 103(4):417-453.
  • Garofalo, M.C., Bennett, A., Farese, A.M., Ward, A.A., Taylor-Howell, C., Cui, W., Gibbs, A., Lasio, G., Jackson, W., MacVittie, T.J. (2014) The delayed pulmonary syndrome following acute high-dose irradiation: A rhesus macaque model. J Health Phys 106(1):56-72.

C3. Conducted seminal studies in our laboratory investigating the efficacy of the leukocyte growth factors, neupogen and neulasta to improve survival in nonhuman primates experiencing the H-ARS. These studies contributed to the FDA approval for licensure of these drugs to treat humans exposed to radiation levels that would result in H-ARS.

  • Farese, A.M., Cohen, M.V., Stead, R.B., Jackson III, W., MacVittie, T.J. (2012) Peg-filgrastim, administered in an abbreviated schedule, significantly improves neutrophil recovery after high-dose, radiation-induced myelosuppression in rhesus macaques. Rad Research, 178(5):403-13.
  • Hankey, K.G., Farese A.M., Blaauw, E.C., Gibbs, A.M., Smith, C.P., Katz, B.P., Tong, T., Prado, K.L.,MacVittie, T.J. (2015) Pegfilgrastim Improves Survival of Lethally Irradiated Nonhuman Primates. Radiation Research Radiat Res 83(6): 643-655.
  • Food and Drug Administration. FDA approves Neupogen® for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident. 3-30-2015, http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/AboutMCMi/ucm443245.htm  and http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125031s180lbl.pdf

Clinical Specialty Details

Alumni Professional Achievement Award, College of Health Sciences, Marquette University. 2017

Awards and Affiliations

Ongoing Research Support

SRI/NIAID #HHSN272201500013I;
SRI RFP# DD-052416-1 
MacVittie, TJ (PI) 07/07/2016 to 12/21/2018
Contract Title: Radiation/Nuclear Medical Countermeasure Product Development Support Services.
Project Title: Assess the efficacy of filgrastim on a) mitigating myelosuppression/mortality associated with the H-ARS when administered in a delayed schedule and b) co-morbidities and mortality of a multi-organ injury (MOI) associated with the concurrent GI-ARS, prolonged GI injury and delayed effects to lung and kidney characteristic of the DEARE in NHP exposed to 10 or 11Gy.
Role: Co-PI

Completed Research Support

HHSN272201000046C MacVittie, TJ (PI) 09/30/10 to 12/31/15
Contract Title: Radiation/Nuclear Medical Countermeasure Product Development Support Services.
Program Title: Medical Countermeasures Against Radiological Threats (MCART)
The overarching goal of this Contract/MCART Consortium is the development of medial countermeasures (MCM) to treat the key sequelae of the acute radiation syndrome and delayed effects of acute radiation exposure via the criteria of the FDA animal rule for FDA approval to treat personnel exposed to potentially lethal doses of radiation.
Role: Co-PI

HHS00100201100007C
MacVittie, TJ (PI), 02/11/11 to 03/31/15
Program Title: Advanced Development of AEOL 10150 as a Medical Countermeasure for Pulmonary Injury Associated with ARS and DEARE.
Role: Co-PI

Professional Activity

  • 1974-1978: Medical Technologist, VA Hospital, Durham, NC
  • 1979: Medical Technologist, NortheastBaptistHospital, San Antonio, TX
  • 1979-1983: Medical Technologist, Audie Murphy VA Hospital, San Antonio, TX
  • 1983-1986: Medical Technologist, NIH, Dept. Clinical Pathology, Hematology Division, Bethesda, MD
  • 1986-1987: Research Biologist, Experimental Hematology Department (EXH), Armed Forces Radiobiology Research Institute (AFRRI), Bethesda, MD
  • 1987-1995: Manager Cell Biology Laboratory, EXH, AFRRI, Bethesda, MD
  • 1990-1995: Manager of Extramural Contracts, EXH, AFRRI, Bethesda, MD
  • 1990-1995: Research Investigator, EXH, AFRRI, Bethesda, MD
  • 1995-2013: Research Associate, Faculty, University of Maryland, Baltimore, MD
  • 2013-present: Assistant Professor, Faculty, University of Maryland, Baltimore, MD

Other Experience and Professional Memberships

  • 1974-1987 & 2006- present: American Society of Clinical Pathologists
  • 1989-2014: International Society of Experimental Hematology
  • 1993-2005: Society of Leukocyte Biology
  • 1995- American Society of Hematology
  • 2002-2009: Society for Cell Therapy
  • 2005- Radiation Research Society

Scientific Output and Citations

Authored or co-authored 68 peer-reviewed publications (1 additional manuscript currently under review) and 7 book chapters; 31 invited lectures.

Edit Icon - Click to update your profileUpdate Your Profile